Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.

As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize

09:09am, Friday, 24'th Jul 2026

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.

Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads

05:48am, Friday, 24'th Jul 2026

Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

04:41am, Friday, 24'th Jul 2026

Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity ‌and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry

2 Top Growth Stocks to Buy Right Now Without Any Hesitation

12:30am, Friday, 24'th Jul 2026

There are plenty of reasons to love these companies.

Lilly's Next-Generation Obesity Shot Clears Another Hurdle

07:25pm, Thursday, 23'rd Jul 2026

Eli Lilly & Co.'s next-generation weight-loss shot retatrutide didn't increase overall heart risk in a new study, helping dispel concerns over its potential. The company plans to file for US Food and

There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders

01:38pm, Thursday, 23'rd Jul 2026

Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.

Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds

10:15am, Thursday, 23'rd Jul 2026

Analysts have suggested retatrutide could become a blockbuster weight loss drug if approved. In January, TD Cowen analysts estimated retatrutide could generate $3.8 billion in sales in 2030, while Glo

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

08:15am, Thursday, 23'rd Jul 2026

FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.

Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data

06:48am, Thursday, 23'rd Jul 2026

Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.

Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application

06:47am, Thursday, 23'rd Jul 2026

Eli Lilly ‌on Thursday said two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit an application to the U.S. Food and Drug Administratio

Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

06:45am, Thursday, 23'rd Jul 2026

Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials. The drug delivered significant

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by